Cardiovascular outcome trials of glucose-lowering therapies

Abstract

Choice of glucose-lowering therapy in T2D should be individualised. In view of the benefits seen in CVOTs with SGLT2is and GLP-1RAs, these newer drugs should be the preferred choice.

Citation
Khunti K, Davies MJ, Seidu S. Expert Rev Pharmacoecon Outcomes Res 2020;20:237–49.